

Hanneke Schuitemaker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1707312/publications.pdf>

Version: 2024-02-01

76
papers

10,220
citations

94269

37
h-index

74018

75
g-index

112
all docs

112
docs citations

112
times ranked

14154
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Efficacy of Single-Dose Ad26.COVS.2 Vaccine against Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 2187-2201.	13.9	1,954
2	Interim Results of a Phase 1a Trial of Ad26.COVS.2 Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 1824-1835.	13.9	962
3	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2020, 586, 583-588.	13.7	765
4	Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. <i>Nature</i> , 2012, 482, 89-93.	13.7	452
5	T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. <i>Nature Immunology</i> , 2000, 1, 285-289.	7.0	347
6	Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. <i>Cell</i> , 2015, 163, 1702-1715.	13.5	341
7	Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology. <i>Cell</i> , 2015, 163, 988-998.	13.5	326
8	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. <i>Science</i> , 2015, 349, 320-324.	6.0	303
9	Immunogenicity of Ad26.COVS.2 vaccine against SARS-CoV-2 variants in humans. <i>Nature</i> , 2021, 596, 268-272.	13.7	290
10	Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. <i>Npj Vaccines</i> , 2020, 5, 91.	2.9	286
11	Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. <i>Nature Medicine</i> , 2020, 26, 1694-1700.	15.2	275
12	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). <i>Lancet</i> , The, 2018, 392, 232-243.	6.3	269
13	Safety and Immunogenicity of Novel Adenovirus Type 26 and Modified Vaccinia Ankara Vectored Ebola Vaccines. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1610.	3.8	266
14	Immunogenicity of the Ad26.COVS.2 Vaccine for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1535.	3.8	260
15	A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. <i>Nature Communications</i> , 2015, 6, 8143.	5.8	248
16	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. <i>Nature</i> , 2016, 540, 284-287.	13.7	246
17	Prospects for a safe COVID-19 vaccine. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	204
18	Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COVS.2 Vaccination. <i>New England Journal of Medicine</i> , 2021, 385, 951-953.	13.9	192

#	ARTICLE	IF	CITATIONS
19	Cross-reactive Neutralizing Humoral Immunity Does Not Protect from HIV Type 1 Disease Progression. <i>Journal of Infectious Diseases</i> , 2010, 201, 1045-1053.	1.9	156
20	An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. <i>Nature Microbiology</i> , 2017, 2, 16199.	5.9	144
21	Final Analysis of Efficacy and Safety of Single-Dose Ad26.COVS.2.S. <i>New England Journal of Medicine</i> , 2022, 386, 847-860.	13.9	132
22	Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. <i>Aids</i> , 2009, 23, 2405-2414.	1.0	112
23	A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers. <i>Cell Reports</i> , 2018, 23, 584-595.	2.9	93
24	Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. <i>Aids</i> , 2009, 23, 19-28.	1.0	79
25	Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. <i>PLoS Pathogens</i> , 2015, 11, e1005110.	2.1	78
26	Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years. <i>Journal of Infectious Diseases</i> , 2020, 222, 979-988.	1.9	78
27	A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. <i>PLoS ONE</i> , 2018, 13, e0192312.	1.1	64
28	Transmission of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Variants Following Deliberate Injection of Blood from a Patient with AIDS: Characteristics and Natural History of the Virus. <i>Clinical Infectious Diseases</i> , 1995, 21, 556-560###.	2.9	58
29	Longitudinal Analysis of Early HIV-1-Specific Neutralizing Activity in an Elite Neutralizer and in Five Patients Who Developed Cross-Reactive Neutralizing Activity. <i>Journal of Virology</i> , 2012, 86, 2045-2055.	1.5	58
30	Immunogenicity and efficacy of one and two doses of Ad26.COVS.2.S COVID vaccine in adult and aged NHP. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	55
31	Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats. <i>Vaccine</i> , 2015, 33, 5406-5414.	1.7	53
32	Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species. <i>PLoS ONE</i> , 2012, 7, e44115.	1.1	52
33	Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2021, 39, 3081-3101.	1.7	51
34	Low-dose Ad26.COVS.2.S protection against SARS-CoV-2 challenge in rhesus macaques. <i>Cell</i> , 2021, 184, 3467-3473.e11.	13.5	49
35	Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate. <i>Npj Vaccines</i> , 2020, 5, 112.	2.9	45
36	A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine. <i>Annals of Internal Medicine</i> , 2021, 174, 585-594.	2.0	44

#	ARTICLE	IF	CITATIONS
37	Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. <i>Nature Medicine</i> , 2020, 26, 498-501.	15.2	43
38	Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults. <i>Journal of Infectious Diseases</i> , 2021, 223, 699-708.	1.9	43
39	Macrophage-tropic HIV-1 variants: initiators of infection and AIDS pathogenesis?. <i>Journal of Leukocyte Biology</i> , 1994, 56, 218-224.	1.5	41
40	PER.C6 ⁺ cells as a serum-free suspension cell platform for the production of high titer poliovirus: A potential low cost of goods option for world supply of inactivated poliovirus vaccine. <i>Vaccine</i> , 2013, 31, 850-856.	1.7	40
41	Protective efficacy of Ad26.COVS against SARS-CoV-2 B.1.351 in macaques. <i>Nature</i> , 2021, 596, 423-427.	13.7	40
42	HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. <i>Retrovirology</i> , 2013, 10, 102.	0.9	39
43	Ad26.COVS protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease. <i>Npj Vaccines</i> , 2021, 6, 39.	2.9	38
44	Immunity elicited by natural infection or Ad26.COVS vaccination protects hamsters against SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021, 13, eabj3789.	5.8	32
45	Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations. <i>Npj Vaccines</i> , 2019, 4, 54.	2.9	27
46	A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	26
47	Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice. <i>Npj Vaccines</i> , 2020, 5, 49.	2.9	24
48	Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques following SARS-CoV-2 Vaccination and Infection. <i>Journal of Virology</i> , 2021, 95, .	1.5	24
49	SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COVS vaccination predict durable protection in rhesus macaques. <i>Nature Communications</i> , 2021, 12, 5877.	5.8	21
50	HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds. <i>Retrovirology</i> , 2016, 13, 48.	0.9	20
51	Genome-Wide Association Study on the Development of Cross-Reactive Neutralizing Antibodies in HIV-1 Infected Individuals. <i>PLoS ONE</i> , 2013, 8, e54684.	1.1	20
52	Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers. <i>Aids</i> , 2014, 28, 1237-1240.	1.0	19
53	Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. <i>Lancet HIV</i> , 2014, 1, e41-e48.	2.1	17
54	Production of high titer attenuated poliovirus strains on the serum-free PER.C6 ⁺ cell culture platform for the generation of safe and affordable next generation IPV. <i>Vaccine</i> , 2015, 33, 6611-6616.	1.7	16

#	ARTICLE	IF	CITATIONS
55	Durable antibody responses elicited by 1 dose of Ad26.COVS.2 and substantial increase after boosting: 2 randomized clinical trials. <i>Vaccine</i> , 2022, 40, 4403-4411.	1.7	16
56	Sensitivity of Primary R5 HIV-1 to Inhibition by Rantes Correlates with Sensitivity to Small-Molecule R5 Inhibitors. <i>Antiviral Therapy</i> , 2005, 10, 231-237.	0.6	15
57	Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform. <i>PLoS ONE</i> , 2017, 12, e0174728.	1.1	14
58	Identification of Genes Whose Expression Profile Is Associated with Non-Progression towards AIDS Using eQTLs. <i>PLoS ONE</i> , 2015, 10, e0136989.	1.1	13
59	The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization. <i>Journal of Virology</i> , 2022, 96, JVI0155221.	1.5	13
60	A homologous or variant booster vaccine after Ad26.COVS.2 immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques. <i>Science Translational Medicine</i> , 2022, 14, eabm4996.	5.8	13
61	Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques. <i>Nature Communications</i> , 2022, 13, .	5.8	12
62	The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 1135-1142.	0.5	11
63	Immunogenicity and efficacy of Ad26.<sc>COVS.2</sc>: An adenoviral vector-based <sc>COVID-19</sc> vaccine. <i>Immunological Reviews</i> , 2022, 310, 47-60.	2.8	10
64	An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6 cell culture platform is immunogenic and safe in a non-human primate model. <i>Vaccine</i> , 2018, 36, 6979-6987.	1.7	9
65	Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models. <i>Vaccine</i> , 2022, 40, 934-944.	1.7	9
66	Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COVS.2 Coronavirus Disease 2019 Vaccine. <i>Journal of Infectious Diseases</i> , 2022, 226, 979-982.	1.9	7
67	Low level of HIV-1 evolution after transmission from mother to child. <i>Scientific Reports</i> , 2014, 4, 5079.	1.6	6
68	Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users. <i>Viruses</i> , 2019, 11, 384.	1.5	6
69	Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6 cell-line: a phase 1 randomized controlled trial in adults. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1366-1373.	1.4	6
70	Durability and expansion of neutralizing antibody breadth following Ad26.COVS.2 vaccination of mice. <i>Npj Vaccines</i> , 2022, 7, 23.	2.9	6
71	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques. <i>Npj Vaccines</i> , 2022, 7, 53.	2.9	4
72	Gag sequence variation in a human immunodeficiency virus type 1 transmission cluster influences viral replication fitness. <i>Journal of General Virology</i> , 2013, 94, 354-359.	1.3	2

#	ARTICLE	IF	CITATIONS
73	Passive transfer of Ad26.COVID.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters. <i>Npj Vaccines</i> , 2022, 7, 2.	2.9	2
74	RECENT DEVELOPMENT ON RESEARCH IN AIDS PATHOGENESIS. <i>Vox Sanguinis</i> , 1994, 67, 133-136.	0.7	1
75	Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6 ⁺ cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-11.	1.4	1
76	Use of Immunological and Viral Parameters to Predict Progression of HIV Infection During Natural Course and Antiretroviral Treatment. <i>BioDrugs</i> , 1997, 8, 243-249.	2.2	0